394 related articles for article (PubMed ID: 32971941)
1. Clinical Evidence of Antidepressant Effects of Insulin and Anti-Hyperglycemic Agents and Implications for the Pathophysiology of Depression-A Literature Review.
Woo YS; Lim HK; Wang SM; Bahk WM
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32971941
[TBL] [Abstract][Full Text] [Related]
2. Metformin Promotes Anxiolytic and Antidepressant-Like Responses in Insulin-Resistant Mice by Decreasing Circulating Branched-Chain Amino Acids.
Zemdegs J; Martin H; Pintana H; Bullich S; Manta S; Marqués MA; Moro C; Layé S; Ducrocq F; Chattipakorn N; Chattipakorn SC; Rampon C; Pénicaud L; Fioramonti X; Guiard BP
J Neurosci; 2019 Jul; 39(30):5935-5948. PubMed ID: 31160539
[TBL] [Abstract][Full Text] [Related]
3. Possible role of GLP-1 in antidepressant effects of metformin and exercise in CUMS mice.
Liu W; Liu J; Huang Z; Cui Z; Li L; Liu W; Qi Z
J Affect Disord; 2019 Mar; 246():486-497. PubMed ID: 30599373
[TBL] [Abstract][Full Text] [Related]
4. Repositioning of diabetes treatments for depressive symptoms: A systematic review and meta-analysis of clinical trials.
Moulton CD; Hopkins CWP; Ismail K; Stahl D
Psychoneuroendocrinology; 2018 Aug; 94():91-103. PubMed ID: 29775878
[TBL] [Abstract][Full Text] [Related]
5. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
[TBL] [Abstract][Full Text] [Related]
6. Association between diabetes and mood disorders and the potential use of anti-hyperglycemic agents as antidepressants.
Grigolon RB; Brietzke E; Mansur RB; Idzikowski MA; Gerchman F; De Felice FG; McIntyre RS
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Dec; 95():109720. PubMed ID: 31352032
[TBL] [Abstract][Full Text] [Related]
7. Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients.
Rogliani P; Matera MG; Calzetta L; Hanania NA; Page C; Rossi I; Andreadi A; Galli A; Coppola A; Cazzola M; Lauro D
Respir Med; 2019; 154():86-92. PubMed ID: 31228775
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity.
Yaribeygi H; Sathyapalan T; Sahebkar A
Life Sci; 2019 Oct; 234():116776. PubMed ID: 31425698
[TBL] [Abstract][Full Text] [Related]
9. Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach.
Nadeau DA
Postgrad Med; 2013 May; 125(3):112-26. PubMed ID: 23748512
[TBL] [Abstract][Full Text] [Related]
10. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
Sloan LA
J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
[TBL] [Abstract][Full Text] [Related]
11. Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus.
Guo M; Mi J; Jiang QM; Xu JM; Tang YY; Tian G; Wang B
Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):650-6. PubMed ID: 24862430
[TBL] [Abstract][Full Text] [Related]
12. A systematic review of the antidepressant effects of glucagon-like peptide 1 (GLP-1) functional agonists: Further link between metabolism and psychopathology: Special Section on "Translational and Neuroscience Studies in Affective Disorders". Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders.
Pozzi M; Mazhar F; Peeters GGAM; Vantaggiato C; Nobile M; Clementi E; Radice S; Carnovale C
J Affect Disord; 2019 Oct; 257():. PubMed ID: 31153593
[TBL] [Abstract][Full Text] [Related]
13. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
Tonneijck L; Muskiet MHA; Smits MM; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
Diabetes Obes Metab; 2017 Dec; 19(12):1669-1680. PubMed ID: 28449402
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
15. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
16. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
Ji Q
Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
[TBL] [Abstract][Full Text] [Related]
17. Antidepressant activity of anti-hyperglycemic agents in experimental models: A review.
Essmat N; Soliman E; Mahmoud MF; Mahmoud AAA
Diabetes Metab Syndr; 2020; 14(5):1179-1186. PubMed ID: 32673838
[TBL] [Abstract][Full Text] [Related]
18. PPAR-γ Agonists for the Treatment of Major Depression: A Review.
Colle R; de Larminat D; Rotenberg S; Hozer F; Hardy P; Verstuyft C; Fève B; Corruble E
Pharmacopsychiatry; 2017 Mar; 50(2):49-55. PubMed ID: 27978584
[No Abstract] [Full Text] [Related]
19. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
Østergaard L; Frandsen CS; Madsbad S
Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
[TBL] [Abstract][Full Text] [Related]
20. GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus.
Dahiya L; Kaur R; Kumar R; Kumar M; Palta K
Curr Diabetes Rev; 2020; 16(4):279-292. PubMed ID: 31057118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
